TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02846831

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-day intervention with sensor-augmented pump therapy
Description: A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 12-day intervention with single-hormone closed-loop strategy
Description: A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Tandem Diabetes Care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Tandem Diabetes Care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Dexcom G5 Platinum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Dexcom G5 Platinum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT03175978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF/MTX
Description: 765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
Study: NCT02655133

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaglobin®
Description: Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic solution
Description: Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
Study: NCT02921542

Intervention type: DEVICE
Intervention: Laser Atherectomy
Description: The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).

Intervention type: DEVICE
Intervention: Laser Atherectomy
Description: The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).

Intervention type: DEVICE
Intervention: Laser Atherectomy
Description: The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).

Intervention type: DEVICE
Intervention: Laser Atherectomy
Description: The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
Study: NCT01427881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSCT
Study: NCT02465645

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol + Simvastatin
Study: NCT01590459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-509
Description: 50 mg oral tablet
Study: NCT04139460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-D
Description: After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT-P
Description: After randomization, devices will be implanted as soon as possible (within 2 weeks).
Study: NCT00782561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FG-3019
Description: FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
Study: NCT02369549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micro-particle Curcumin
Description: as described in Arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks, smells, tastes and feels exactly like the Curcumin capsules.
Study: NCT00575380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AzaSite Eye Drops
Description: One drop two times a day for two days and once a day for the next five days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox Eye Drops
Description: One drop three times a day for seven days
Study: NCT03798340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibratory perturbed task-specific movement training
Description: The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional task-oriented facilitation
Description: Reach-to-grasp training and hand release training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor training
Description: Targeted to goals that are relevant to the sensorimotor facilitation of the patient

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensorimotor training
Description: Targeted to goals that are relevant to the sensorimotor facilitation of the patient
Study: NCT02600208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CliniMACs
Description: Depletion of Alpha Beta T cells in the PBSC graft
Study: NCT04335188

Intervention type: OTHER
Intervention: Prospective oberservational registry
Description: Non interventional study.
Study: NCT04252287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo capsules orally once daily.
Study: NCT00456482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide 0.59mg
Description: Fluocinolone Acetonide Intravitreal Implant 0.59 mg
Study: NCT00456482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide 2.1mg
Description: Fluocinolone Acetonide Intravitreal Implant 2.1 mg
Study: NCT06199960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doustim protocol
Description: In Duostim group, the follicular stimulation will be started with a ﬁxed dose of 150 IU of rFSH and HMG 75 IU for 4 days. Daily administration of a GnRH antagonist will be started when the leading follicle are 13-14mm in diameter and continue until the day of the trigger of the ovulation. Five days after the ﬁrst oocyte retrieval second gonadotropin stimulation will be started identical to the ﬁrst one..
Study: NCT01590459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VX-509 matching placebo
Description: 0 mg oral tablet
Study: NCT01951937

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Meals
Description: Meals containing salmon

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No fish meals
Study: NCT00795145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous, Placebo control for blinding, Normal Saline, Single dose
Study: NCT02696629

Intervention type: PROCEDURE
Intervention: upper airway surgery
Description: Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery

Intervention type: DEVICE
Intervention: Continues positive airway pressure
Description: Participants who are treated with continues positive airway pressure during sleep.

Intervention type: BEHAVIORAL
Intervention: education and follow up
Description: Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
Study: NCT01624558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-line Carbon filter (Vapor-Clean)
Description: Carbon filter placed in anesthesia breathing circuit.
Study: NCT01569906

Intervention type: RADIATION
Intervention: Narrowband Ultraviolet B phototherapy
Description: Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
Study: NCT03279666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tenaculum replacement
Description: Tenaculum replacement during colposcopic biopsy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tenaculum replacement
Description: Tenaculum replacement during colposcopic biopsy
Study: NCT01871818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined program
Description: Combined program with physiotherapy, endurance training and resistance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy in private practice
Description: Physiotherapy in private practice
Study: NCT01459549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y choledochojejunostomy
Description: Roux-en-Y choledochojejunostomy must be operated
Study: NCT01981356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
Study: NCT02315885

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol administration; Placebo administration
Description: consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol administration; Placebo administration
Description: consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol administration; Placebo administration
Description: consumption of 3 alcohol doses (2 regular and one placebo) each within 2h on separate days
Study: NCT02180113

Intervention type: DEVICE
Group type: OTHER
Intervention: Fibroscan® examination
Description: Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
Study: NCT02876939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No kinesiology tape around the hip, knee and ankle joints
Description: Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
Study: NCT01130064

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QAX576
Description: every 3 weeks via intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every 3 weeks via intravenous infusion
Study: NCT04201119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxiris
Description: Oxiris membrane used on the Prismaflex device (Baxter) dedicated to that type of membrane at blood pump flow of 450 ml min-1
Study: NCT02712866

Intervention type: DRUG
Intervention: Vedolizumab
Description: Administration of intravenous Vedolizumab in inflammatory bowel disease patients
Study: NCT01066741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeodent®
Description: Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.4% Sodium Bicarbonate solution
Description: Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
Study: NCT01472536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequestration
Description: Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
Study: NCT00237107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curretage
Study: NCT03231436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose of 12.5mg bupivacaine
Description: Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Height-adjusted dose of bupivacaine
Description: Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
Study: NCT02063607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon lambda

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon lambda
Study: NCT02197299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Study: NCT02795351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single oral administration of active or placebo one week apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03648476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICAN
Description: A 6-week group therapy sessions once a week for 90-120 minutes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ICAN
Description: A 6-week group therapy sessions once a week for 90-120 minutes.
Study: NCT04824196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular visual cues therapy
Description: Pelvic rolling to right and left with head movement and stop first on right side for 3 minutes. Do this exercise in front of the mirrorAnterior, posterior, left, and right rectilinear stimulation activities on a therapeutic ball. Anterior, posterior, left and right rectilinear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: propriocetion exercise
Description: 1. Alternate knee flexion-extension with extended trunk posture using both hands for support.~2. Hip and knee flexion-extension with swiss ball between the back and wall.~3. Hip raises lying with their back on the floor with both legs on the swiss ball. Upper limbs leaning on the floor to help with the exercises. then all exercise are perfomed on gym ball
Study: NCT00856271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: oral tablets, once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: capsules, once daily for 8 weeks
Study: NCT00795145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 900 mg
Description: Intravenous, 900 mg linezolid, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg
Description: Intravenous, 1200 mg linezolid, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous, Placebo control for blinding, Normal Saline, Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg
Description: Intravenous, 600 mg linezolid, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid 1200 mg
Description: Intravenous, 1200 mg linezolid, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: Oral, 400 mg moxifloxacin, single dose
Study: NCT04217148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone, iv, 40 mg/d, for 4 days (The 4-day course of dexamethasone was repeated in the case of lack of response by day 10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA, po,10mg bid, for 12 weeks
Study: NCT02991560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Physioytherapy
Description: The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Physioytherapy
Description: The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Athletic taping
Description: By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
Study: NCT04504006

Intervention type: PROCEDURE
Intervention: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
Description: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL)
Study: NCT01866176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilizing Knee Brace
Description: Brace with no valgus action

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valgus Knee Brace
Description: Valgus brace with traditional three point bending system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Knee Brace
Description: Brace with new mechanism to decrease the knee loading.
Study: NCT03566238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250 (odevixibat)
Description: A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A4250 (odevixibat)
Description: A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical in appearance to active drug (A4250).
Study: NCT00665951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 200/50mg; 2 tablets; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
Study: NCT01847924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC901
Description: 24 weeks intervention with orally MLC901. 2 capsules 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 24 weeks intervention with orally placebo. 2 capsules 3 times a day
Study: NCT03730740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25mg
Description: Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
Study: NCT03110016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
Study: NCT01962649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICG

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical molecular imaging